Organometallic compounds in oncology: implications of novel organotins as antitumor agents

Angela Alama, Bruno Tasso, Federica Novelli, Fabio Sparatore

Research output: Contribution to journalArticle


Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining growing importance in oncology. The impressive clinical effectiveness of cisplatin is limited by significant side effects and the emergence of drug resistance. Thus, novel classic and unconventional PtII and PtIV complexes have been introduced in therapy or are presently in advanced clinical trials. Moreover, innovative non-platinum metal-based antitumor agents, whose activity does not rely on direct DNA damage and may involve proteins and enzymes, have been developed. Gold and tin derivatives are enjoying an increasing interest and appear very promising as potential drug candidates.

Original languageEnglish
Pages (from-to)500-508
Number of pages9
JournalDrug Discovery Today
Issue number9-10
Publication statusPublished - May 2009

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Organometallic compounds in oncology: implications of novel organotins as antitumor agents'. Together they form a unique fingerprint.

  • Cite this